Insmed | INSM - Current Assets


Insmed reported $1.79B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Cytokinetics USD 916.97M 60.37M Dec/2025
DBV Technologies USD 88.88M 32.36M Sep/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
Heron Therapeutics USD 238.07M 8.67M Dec/2025
Insmed USD 1.79B 137.6M Dec/2025
Novartis USD 28.2B 2.26B Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025